Local and systemic changes in the immune system with the participation of soluble mediators IL-21 and IL-22 indicate the participation of these parameters in the development of ovarian cancer and may participate in pro and anti-inflammatory activation involving the tested cytokines. The gene discussed is IL22; the disease is ovarian cancer.